Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback